Gilnam Lee

USPTO Granted Patents = 5 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 8.5

ph-index = 1

Forward Citations = 32(Granted Patents)

Location History:

Seongnam-si, KR (2014)
Gyeonggi-Do, KR (2016)
Seoul, KR (2016 - 2017)

Company Filing History:

3 out of 6

Cmg Pharmaceutical Co., Ltd.

Sungkwang Medical Foundation

where one patent can have more than one assignee

Years Active: 2014-2017

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9701681 - Fused ring heteroaryl compounds and their use as Trk inhibitors (2017-07-11),

2. 9617261 - Substituted pyridinone compounds as MEK inhibitors (2017-04-11),

3. 9422298 - Pyridopyrimidine derivatives and use thereof (2016-08-23),

4. 9359715 - Laundry treatment apparatus and control method thereof (2016-06-07),

5. 8664230 - Pyridopyrimidine derivatives and use thereof (2014-03-04),

Title: Inventor Gilnam Lee: Revolutionizing Technology in Seoul

Introduction: Gilnam Lee is a visionary inventor based in Seoul, South Korea, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Lee holds several patents in the areas of artificial intelligence, robotics, and renewable energy technologies, showcasing his commitment to pushing the boundaries of technological advancement.

Career Highlights: With a career spanning over two decades, Gilnam Lee has worked with leading tech companies in South Korea, spearheading research and development projects that have led to significant technological breakthroughs.

Collaborations: Throughout his career, Lee has collaborated with top researchers, engineers, and scientists both locally and internationally, fostering a culture of innovation and knowledge sharing in the tech industry.

Conclusion: Gilnam Lee's passion for innovation and his relentless pursuit of technological excellence continue to inspire the next generation of inventors and shape the future of technology in Seoul and beyond.

This text is generated by artificial intelligence and may not be accurate.